Among adults with overweight or obesity taking tirzepatide, receiving apitegromab every four weeks for 24 weeks results in 1.9 kilograms less loss of lean mass and 54.9% more preservation of lean mass compared to placebo, even when total weight loss is the same.
See the scientific wording
In adults with overweight or obesity receiving tirzepatide, weekly administration of apitegromab at 10 mg/kg every four weeks for 24 weeks reduces lean mass loss by 1.9 kg compared to placebo, preserving 54.9% more lean mass despite equivalent total weight loss.
Very strong evidence
Randomized trialsOne high-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2026
When people with extra weight take a weight-loss drug called tirzepatide, they often lose muscle too. But when they also get a special muscle-saving drug called apitegromab every four weeks, they keep nearly 2 kilograms more muscle than those on a placebo—even though both groups lose the same total weight.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug blocks a natural signal that stops muscle growth, allowing muscles to keep building and breaking down less protein even when the body is losing weight. This keeps muscle mass from shrinking while fat is lost.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Among adults with overweight or obesity taking tirzepatide, receiving apitegromab every four weeks for 24 weeks results in 1.9 kilograms less loss of lean mass and 54.9% more preservation of lean mass compared to placebo, even when total weight loss is the same.
Mechanism
1 studyA drug blocks a natural brake on muscle growth, so muscles keep building protein and break down less of it, even when the body is losing weight. This keeps muscle from shrinking while fat is lost.
A drug blocks a natural signal that stops muscle growth, allowing muscles to keep building and breaking down less protein even when the body is losing weight. This keeps muscle mass from shrinking while fat is lost.
A monoclonal antibody binds to inactive precursors of myostatin in the bloodstream, preventing their conversion into the active form of the protein
Inhibition of active myostatin removes suppression of satellite cell activation and muscle protein synthesis, while reducing ubiquitin-proteasome-mediated protein degradation
The net increase in muscle protein accumulation counteracts the catabolic pressure from weight-loss-inducing pharmacotherapy, maintaining lean tissue mass despite systemic energy deficit
Evidence from Studies
Supporting (1)
Community contributions welcome
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
When people with extra weight take a weight-loss drug called tirzepatide, they often lose muscle too. But when they also get a special muscle-saving drug called apitegromab every four weeks, they keep nearly 2 kilograms more muscle than those on a placebo—even though both groups lose the same total weight.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Apitegromab vs Placebo on Lean Mass Preservation in Tirzepatide-Treated Adults with Overweight or Obesity
Population: Adults with overweight or obesity receiving tirzepatide; Intervention: Apitegromab 10 mg/kg every four weeks; Comparator: Placebo; Outcome: Change in lean mass over 24 weeks; Duration: 24 weeks
Double-Blind, Placebo-Controlled Trial of Apitegromab on Lean Mass Preservation in Tirzepatide-Treated Adults with Overweight or Obesity
Population: Adults with overweight or obesity on tirzepatide; Intervention: Apitegromab 10 mg/kg every four weeks; Comparator: Placebo; Outcome: Change in lean mass and total weight loss over 24 weeks; Duration: 24 weeks
Prospective Cohort Study of Apitegromab Use and Lean Mass Outcomes in Adults with Overweight or Obesity on Tirzepatide
Population: Adults with overweight or obesity on tirzepatide; Exposure: Apitegromab 10 mg/kg every four weeks; Comparator: Non-exposed cohort; Outcome: Lean mass change over 24 weeks; Duration: 24 weeks
In Vitro Analysis of Apitegromab's Effect on Human Skeletal Muscle Cell Protein Synthesis and Degradation Pathways
Population: Human skeletal muscle cells; Intervention: Apitegromab at 10 mg/kg equivalent concentration; Comparator: Control medium; Outcome: Myostatin pathway inhibition and protein turnover rates; Duration: 72 hours
Animal Model Study of Apitegromab on Lean Mass Preservation During Pharmacologic Weight Loss in Obese Mice
Population: Diet-induced obese mice; Intervention: Apitegromab at 10 mg/kg every four weeks; Comparator: Vehicle control; Outcome: Lean mass and fat mass changes over 24 weeks; Duration: 24 weeks